knowledge -WSS

knowledge

author：comprehensive 2025-09-03 18:35:59 - browse：3956

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： How to pay for weight loss drugs and save Medicare

WSS

CDC director unscathed in first congressional testimony

BIO selects John Crowley as new CEO

HHS secretary Becerra pressed on Change HealthCare cyberattack

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

CDC director unscathed in first congressional testimony

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

hotspot

knowledge

explore

Drug repurposing or repositioning? The language matters

With clinical trial data readouts, here's how to spot spin

Malaria cases in Florida and Texas: Here’s what you need to know

First U.S. drug developed to treat liver disease MASH is approved

Medical leaders decry Supreme Court decision on affirmative action

What to do when lifesaving products contribute to climate change

The cancer drug shortage isn’t new — and neither are the solutions

Disappointing trial forces Pfizer to pivot on obesity medicine plans

United colonoscopy coverage change 'may cost lives,' doctors say

BIO selects John Crowley as new CEO

knowledge

What to do when lifesaving products contribute to climate change

President Biden's budget: Here's what you might have missed

John Green on his newest strategy for fighting tuberculosis

RaDonda Vaught links Vanderbilt hospital issues to patient death

UnitedHealth’s Optum accused of antitrust violations in California

The EPA's new lead rule: How one expert crunched the numbers

explore

focus

entertainment

hotspot